文献速递临床试验与 GCP基础与转化研究

谷红注射液治疗冠状动脉微血管疾病疗效与安全性的随机对照试验方案

Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-01-13

本研究为多中心、随机、平行、开放标签、双盲、安慰剂对照临床试验,计划纳入260例冠状动脉微血管疾病患者,按1:1随机分配至谷红注射液组或对照组,疗程10天并随访8周,主要结局为治疗有效性,旨在评估谷红注射液对比安慰剂的疗效与安全性。

要点

  • 试验采用多中心随机双盲安慰剂对照设计,计划纳入260例CMVD患者。
  • 主要结局为治疗有效性,次要结局涵盖中医证候积分、心绞痛发作频率等。
  • 试验遵循中国食品药品监督管理局(CFDA)原则与法规设计。

核心结论

  • 该试验旨在为谷红注射液治疗冠状动脉微血管疾病提供高质量的疗效与安全性证据。

研究设计与样本

  • 多中心、随机、平行臂、开放标签、双盲、安慰剂对照临床试验,计划纳入260例合格患者,按1:1随机分配至试验组或对照组。
  • 疗程为连续10天,随访8周。

关键数值与推荐

  • 主要结局为治疗有效性。
  • 次要结局包括中医证候定量评分、心绞痛平均发作频率、心电图改变、炎症反应、内皮功能指标及心肌代谢物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronary microvascular disease (CMVD) can be described as one of the cardiovascular diseases with normal coronary angiography but evidence of myocardial ischemia or microcirculatory lesions, often presenting as angina pectoris attacks. Coronary artery microtubular dysfunction is one of the pathogenic features of coronary heart disease, but its occurrence and development and the current CMVD-intervention therapy needs further research. Chinese traditional medicine (TCM) has advantages for the treatment of cardiovascular diseases. Hence, this article describes an ongoing randomized controlled clinical trial based on the theory of TCM for the purpose of evaluating the efficacy and safety of Guhong injection versus placebo in patients with CMVD. METHODS/DESIGN: This is a multicenter, randomized, parallel-arm, open-label, double-blind, placebo-controlled clinical trial. A total of 260 eligible patients will be allocated and randomly assigned, in a ratio of 1:1, to either the experimental group or the control group. The treatment course is 10 consecutive days, and with an 8-week follow-up. The primary outcome is therapeutic efficacy. Secondary outcomes include the quantitative score of TCM syndromes (a series of TCM symptoms and signs of coronary heart disease), the average frequency of anginal attacks, electrocardiogram (ECG) changes, inflammatory response, endothelial function indicators and myocardial metabolites. DISCUSSION: This trial is strictly designed in accordance with principles and regulations issued by the China Food and Drug Administration (CFDA). The results should provide high-quality evidence on the efficacy and safety of Guhong injection in the treatment of CMVD. TRIAL REGISTRATION: Chinese Clinical Trials Registry, ID: ChiCTR1900022902. Registered on 27 April 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Jieqin Z, Shuling L, Hairong C, et al. Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial. Trials. 2020. PMID: 31931853. doi:10.1186/s13063-019-3990-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。